// App-Quantinova.ai

: Combination Therapy of Nivolumab in First Line and Relapsed/Refractory Classic Hodgkin's Lymphoma: A Systematic Review and Meta-Analysis of Clinical Trials

Researchers

Presenter

  • Kanak Parmar

Principal Investigators

  • Raga Dwarampudi

  • Lukman Tijani

  • Silvia Jakubski

  • Shabnam Rehman

Medical Centers

  • Hematology Oncology Department, Texas Tech University Health Science Center, Lubbock, TX

  • Vydehi Institute of Medical Sciences and Research Centre, Bangalore, India

  • Texas Tech University Health Sciences Center, Lubbock, TX

  • Southwest Cancer Center, Texas Tech University Health Science Center, Lubbock, TX

Locations

  • United States

  • India

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hodgkin's Lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved